|
Delayed
Canadian Securities Exchange
09:31:33 2026-11-02 EST
|
5-day change | 1st Jan Change | ||
| 0.0250 CAD | 0.00% |
|
0.00% | - |
| Market Cap | 184K 168K 155K 140K 263K 17.17M 275K 1.87M 743K 9.28M 690K 675K 29.39M | P/E 2024 |
1.22x | P/E 2025 | -2.21x |
|---|---|---|---|---|---|
| Enterprise Value | 245K 224K 207K 187K 351K 22.91M 368K 2.5M 992K 12.38M 921K 901K 39.22M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
67.71% | Yield 2024 * |
-
| Yield 2025 | - |
Canadian Securities ExchangeCAD
| Markets | Quality | ||
|---|---|---|---|
Canadian Securities Exchange
| NSHS.X | Delayed | |
| NSHSF | Delayed | ||
| 2CG | Delayed | ||
| 2CG | Delayed |
| 1 month | +25.00% | ||
| 3 months | +25.00% | ||
| 6 months | +25.00% |
| 1 month | 0.02 | 0.02 | |
| Current year | 0.02 | 0.03 | |
| 1 year | 0.02 | 0.03 | |
| 3 years | 0 | 0.18 | |
| 5 years | 0 | 0.29 | |
| 10 years | 0 | 23.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Kaufman
CTO | Chief Tech/Sci/R&D Officer | - | 2012-12-31 |
Bennett Liu
DFI | Director of Finance/CFO | 33 | 2017-10-31 |
Toby Lim
CEO | Chief Executive Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Iverson
CHM | Chairman | 74 | 2019-07-09 |
Toby Lim
BRD | Director/Board Member | - | 2017-11-16 |
Richard Kaufman
BRD | Director/Board Member | - | 2017-11-16 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/17/21 | Other | Director | 0 | 0.0000% | ||
| 9/17/21 | Other | Director | 0 | 0.0000% | ||
| 9/17/21 | Sell | Chairman | 338,956 | 6.2564% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | +66.67% | 179K | ||
| -1.91% | -5.05% | +29.12% | +126.78% | 1,232B | ||
| -2.37% | -5.98% | +31.63% | +77.82% | 656B | ||
| -1.13% | -3.79% | +21.63% | +104.82% | 506B | ||
| -1.04% | -1.80% | +28.69% | +68.33% | 382B | ||
| -4.08% | -9.77% | +39.50% | +29.13% | 340B | ||
| -3.22% | -5.20% | +24.48% | +50.97% | 294B | ||
| -2.51% | -4.49% | -2.15% | +31.64% | 278B | ||
| -0.72% | -5.74% | +28.58% | +65.91% | 240B | ||
| -1.21% | -0.54% | +30.44% | +119.80% | 210B | ||
| Average | -1.73% | -2.07% | +23.19% | +74.19% | 414B | |
| Weighted average by Cap. | -1.92% | -2.67% | +27.02% | +87.24% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | 263K 240K 222K 201K 377K 24.59M 394K 2.68M 1.06M 13.29M 988K 967K 42.1M | -84.78K -77.24K -71.51K -64.68K -121K -7.92M -127K -864K -343K -4.28M -318K -311K -13.55M |
| Net Debt | 28.69K 26.14K 24.2K 21.89K 41.06K 2.68M 42.97K 292K 116K 1.45M 108K 105K 4.59M | 61.51K 56.04K 51.88K 46.93K 88.03K 5.74M 92.14K 627K 249K 3.1M 231K 226K 9.83M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-10 | $0.000000 | - | 187 |
- Stock Market
- Stocks
- NSHS.X Stock
Select your edition
All financial news and data tailored to specific country editions
















